Scailyte’s Post

Last week I was at the #BIO2024 exploring partnership opportunities with biotech & pharma companies from around the world. This was a very well organized, vibrant & colorful event in the emerging biotech hub San Diego. Some key insights: - biomarker-driven drug discovery and companion diagnostics is gaining importance outside of oncology, in particular in auto-immunity; - there is a new wave of immuno-oncology drugs, which are showing very promising results with overall response rates of >80% and complete response in >40% of patients in early clinical trials. - genAI and large language models are a hype also in the biotech space - a lot of talk with no results or solid science to back up the claims of these new genAI companies - the bubble gets inflated.